Quipt Home Medical — Q2 2025 Earnings Presentation
26 slides from Quipt Home Medical's earnings presentation, May 13, 2025
Slide 1: Corporate Presentation
Corporate Presentation May 2025 NASDAQ: QIPT A Premier Provider of Clinical Respiratory Care TSX: QIPT
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation (the “Presentation”) about Quipt Home Medical Corp. (the “Company”) is dated as of May 13, 2025. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors an
Slide 3: Quipt Overview
Quipt Overview
Slide 4: Financial and Operational Highlights
Financial and Operational Highlights Strong Foundation for Continued Growth $245.9M $57.9M 850,000+ 314,000 36,000 26 FY2024 FY2024 Annual Patient Referring Active Revenue(1) Adj. EBITDA(1) Deliveries Lives Physicians States ▪ Quipt Home Medical Corp. is a premier provider of clinical respiratory ca
Slide 5: Q2 2025 Investment Highlights
Q2 2025 Investment Highlights $18.2 Million 81% 1.5x $47.8 Million ~10% Cash Flow from Recurring Net Debt to EBITDA Liquidity to fund Insider Ownership Operations(1) Revenue (2) Leverage (2) future growth (2) Consistent Demand for Robust and Resilient Management Expertise Diversified Product Mix Bus
Slide 6: Our History and Path Forward
Our History and Path Forward Our History of Growth Surpassed Surpassed Dual Listed on 15 26 39.3% $100 Million $245 Million NASDAQ States Covered States Covered 4-Year Revenue Revenue May 2021 August 2021 December 2023 A. EBITDA CAGR Fiscal 2021 Fiscal 2024 Our Path Forward ▪ Utilize robust balance
Slide 7: Strong Recurring Revenue Base & Diverse Payor Mix
Strong Recurring Revenue Base & Diverse Payor Mix Revenue Mix (1) Service Mix (1) Payor Mix (1) 1)Updated annually 7
Slide 8: Substantial Operations and Targeted Expansion
Substantial Operations and Targeted Expansion Current Operations ✓ 130 locations across 26 states ✓ Solidified Midwest & Southeast presence ✓ Strengthening coast to coast reach Targeted Expansion ✓ Continued focus on expanding into regions with high prevalence of COPD patients ✓ Significant opportun
Slide 9: Industry Tailwinds Support Organic Growth
Industry Tailwinds Support Organic Growth U.S. Aging (1) & Chronic Condition Population (5) 10,000 Americans turning 65 everyday(1) Millions 200 171 164 157 16 Million COPD patients in the US alone (2) 149 150 141 100 80 Million Estimated US population impacted by Sleep Apnea(3) 73 65 56 50 46 40 31
Slide 10: Complimenting Usage of GLP-1s
Complimenting Usage of GLP-1s Positive Correlation Between Strong Demand and Significant GLP-1s and PAP Therapy Patient Population Data analysis of 1,359,000 patients shows Quipt has experienced no slowdown in CPAP set- positive correlation between GLP-1s and PAP ups and continues to see strong refe
Slide 11: Market Positioning
Market Positioning
Slide 12: Order Life Cycle
Order Life Cycle End-to-End Product Solution Drives Unique Market Positioning Sales Team Sales Touchpoints Verification & Distribution Delivery & Education Revenue Cycle ✓ The Order Life Cycle begins with Quipt’s field sales team and ends with successful collections by Quipt’s revenue cycle team ✓ K
Slide 13: Diversified Product Mix Drives Go-to-Market Strategy
Diversified Product Mix Drives Go-to-Market Strategy Ventilation Sleep Home Oxygen Percussion Custom HME & Other Therapy Therapy Therapy Vests Mobility Services 13
Slide 14: Patient Centric Ecosystem
Patient Centric Ecosystem Connected Healthcare ✓ Live monitoring allows for monitoring treatment plan effectiveness ✓ Identify and drive early intervention, if needed ✓ Reduces hospitalizations and improves outcomes ✓ Remote patient monitoring capabilities Select Respiratory Devices Sleep Apnea Nebu
Slide 15: In-Home Delivery & Set Up
In-Home Delivery & Set Up Responsible Equipment Delivery ✓ In-home (or on-site) delivery across 26 states, and expanding ✓ Quipt has a robust team of certified respiratory therapists ✓ Proper use of prescribed equipment is explained in a 1-on-1 environment to ensure long-term patient compliance, com
Slide 16: Growth Strategy
Growth Strategy
Slide 17: Strategic Growth Initiatives
Strategic Growth Initiatives Organic Growth Debt Management ❖ 8-10% annualized growth target ❖ $47.8 million of current liquidity (cash on ❖ Focus on sales force penetration and continued hand and revolver availability) expansion into continuum markets ❖ Current leverage at 1.5x net debt to EBITDA ❖
Slide 18: Driving Economies of Scale
Driving Economies of Scale Consistent and Strong Margin Profile Revenue (millions) Adj. EBITDA Margin (%) ✓ Scale promotes operating leverage driving margin consistency and strong compounding growth ✓ Since 2018, Quipt has utilized organic growth and synergistic acquisitions to drive scale ✓ Technol
Slide 19: Technology Utilization
Technology Utilization Organizational Efficiency Project Management Revenue Cycle Finance & Accounting ✓ Automated, real-time reporting informs data driven decision making ✓ Uniform reporting structures create opportunities for increased collaboration Order Fulfillment ✓ Commitment to technology wil
Slide 20: Financial Profile
Financial Profile
Slide 21: Financials: Q2 2025
Financials: Q2 2025 Financial Highlights Q2 2025 Revenue & Adj. EBITDA ▪ 23.3% Adjusted EBITDA Margin Revenue Adj. EBITDA (millions) (millions) ▪ 81% Recurring Revenue Transitioned from IFRS to GAAP ▪ Net Debt to Adjusted EBITDA of 1.5x Operational Highlights ▪ Successfully expanded the Company’s pr
Slide 22: Financials: Full Year 2024
Financials: Full Year 2024 Financial Highlights Annual Revenue & Adj. EBITDA ▪ 16.2% increase in Total Revenue Revenue Adj. EBITDA (millions) (millions) ▪ 14.3% increase in Adjusted EBITDA Transitioned from IFRS to GAAP ▪ 23.5% Adjusted EBITDA margin ▪ $35.4mm positive cashflow from operations Opera
Slide 23: Capital Structure & Insider Ownership
Capital Structure & Insider Ownership $76 Million Market Cap* $161 Million Enterprise Value* 43.1 Million ~10% Basic Shares Outstanding Insider Ownership $30.7 Million Senior Credit Facilities (Available) $17.1 Million Cash and Cash Equivalents * As of May 13, 2025 23
Slide 24: Management Team
Management Team Greg Crawford, CEO & Chairman - Greg Crawford is an accomplished executive with more than 30 years of healthcare services experience, focused on the durable medical equipment industry. With a proven track record of success in both the private and public sector, Greg adds extensive op
Slide 25: Board of Directors
Board of Directors Greg Crawford, CEO & Chairman - Greg Crawford is an accomplished executive with more than 30 years of healthcare services experience, focused on the durable medical equipment industry. With a proven track record of success in both the private and public sector, Greg adds extensive
Slide 26: Contact Information
Contact Information Cole Stevens 859-300-6455 [email protected] www.quipthomemedical.com